publication date: Apr. 12, 2019

NCI Trials

NCI Trials for April

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I/II – 10208

A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

University Health Network Princess Margaret Cancer Center LAO

Spreafico, Anna

(416) 946-4501 X 3527

 

Phase II – ADVL1823

Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Children’s Oncology Group

Laetsch, Theodore Willis

(214) 648-3896

 

Phase II – NRG-GY014

A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

NRG Oncology

Eskander, Ramez Nassef

(858) 822-619

 

Phase II – NRG-LU003

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol

NRG Oncology

Shaw, Alice Tsang

(617) 724-4000

 

Phase III – URCC-18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

University of Rochester NCORP Research Base

Jim, Heather S.L.

(813) 745-6369

 

Phase Other – AAML17B4-Q

A Study of the PRMT1-DUSP4 Pathway in Acute Megakaryocytic Leukemia (AMKL)

Children’s Oncology Group

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.